Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 1998

View Archived Issues

Onyx expands ONYX-015 clinical trials in pancreatic cancer

Janssen terminates Avicidin agreement with NeoRx

Intercardia and Astra end Bextra collaboration

Astra initiates atherosclerosis research collaboration with Oxagen

Review of the preclinical activity of GAR-936, a glycylcycline antibiotic with clinical potential

Potent analgesic agents from HMR with additional pharmacological effects

ADIR claims 2-aminoindanes for CNS disorders involving serotonergic system dysfunction

Voriconazole, a promising treatment for serious fungal infections

MMP inhibitors from Bayer particularly useful for osteoarthritis and tumor metastasis

Ono describes new prostanoid receptor ligands

Cell adhesion inhibitors developed by Sumitomo researchers

Abbott uses TE-802 as lead to develop broader spectrum ketolides

Glaxo Wellcome's MMP inhibitor shows potential in treating sepsis in early clinical study

Cubist and Novalon identify small-molecule inhibitors of bacterial enzyme

Xoma presents recombinant variant of rBPI21 with potent antiinfective activity

Inhibitors of bacterial protein identified at Cubist

New echinocandin antifungal discovered by Fujisawa profiled up to phase I at ICAAC

L-084 selected for further development as oral carbapenem prodrug

Pfizer presents a new macrolide that retains good activity in macrolide-resistant strains

Sarawak MediChem initiates phase Ib trial of (+)-calanolide A

Novavax presents BCTP, a novel antimicrobial nanoemulsion, at ICAAC

Icos and Lilly join forces to develop PDE5 inhibitors for sexual dysfunction

Thalomid now available for prescribing in U.S.

First launch for Dainippon's prokinetic agent

First MMP inhibitor cleared for marketing as adjunct in periodontitis

IRL-3630, a bifunctional ETA/ETB receptor antagonist in preliminary testing at Novartis

NO-NSAIDs licensed by NicOx to Astra for pain and inflammation

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...